Maintenance dosing with semaglutide: what it means and what to expect

What does 'maintenance dose' actually mean in the semaglutide titration schedule?

Semaglutide for weight management is not taken at full strength from day one. The titration schedule exists to let your body adjust gradually, reducing the severity of side effects (particularly nausea) that are more pronounced when the dose rises quickly. The Wegovy injection schedule moves through 0.25 mg, 0.5 mg, 1.0 mg and 1.7 mg before arriving at 2.4 mg, with roughly four weeks spent at each step. The 2.4 mg weekly dose is where the medicine settles: no further increases, just a consistent weekly injection at the same strength. That's what maintenance means in this context.

The MHRA approved a higher maintenance option in January 2026 (7.2 mg weekly) initially supplied as three 2.4 mg pens taken on the same day. A dedicated single-dose 7.2 mg pen followed in April 2026, designed with an auto-dosing mechanism and a built-in covered needle. This higher dose is licensed only for adults with a BMI of 30 or above; the titration still starts at 0.25 mg. The full Wegovy dose schedule sets out each step clearly.

A practical habit worth building: once a week, before you inject, note the date in your phone's notes app alongside your current dose. It takes thirty seconds, and it gives your prescriber a clean record at every review, no guessing at how long you've been at this dose.

How does the body respond differently at maintenance compared to the earlier titration steps?

For most people, the gastrointestinal effects that peak during dose increases (nausea, loose stools, burping, reduced appetite) settle considerably once a dose has been stable for a few weeks. Maintenance is not a side-effect-free zone, but the turbulence usually becomes more predictable. Many people find they tolerate 2.4 mg far better after a month at that level than they did in the first fortnight.

What changes more meaningfully at maintenance is the pattern of weight loss. The steepest reductions in body weight tend to occur during the titration phase and the early weeks at the maintenance dose. By the time someone has been at 2.4 mg for several months, weight loss typically slows and may plateau, this is normal physiology, not treatment failure. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at 2.4 mg alongside lifestyle changes; that figure reflects the entire treatment arc, including the plateau that arrives later in the course.

If you've reached maintenance and weight loss has stalled for an extended period, your prescriber is the right person to assess whether the medicine is still working for you, and, if the 7.2 mg pen is now available and clinically appropriate, whether a step up makes sense. Our guide to the Wegovy 1 mg maintenance dose explains where that step sits within the broader titration journey. More on that at the Wegovy maintenance dose page.

Does NICE guidance change what maintenance dosing looks like in practice?

It does, depending on where your prescription comes from. NICE's recommendation for semaglutide (Wegovy) on the NHS (set out in technology appraisal TA875) specifies that treatment should be used for a maximum of two years, within a specialist weight management service offering multidisciplinary support. It also recommends reviewing continuation if less than 5% weight loss has occurred after six months at the maintenance dose. Those are the conditions under which NHS commissioners fund the medicine; the two-year ceiling is part of the cost-effectiveness case made to NICE, not a clinical absolute.

Private prescribing operates under the same clinical evidence but without the two-year cap written into the commissioning rules. A private prescriber still applies clinical judgement: if the medicine isn't producing meaningful benefit, or if the risks outweigh the benefit, they'll say so. The question of whether Wegovy even has a single defined maintenance dose is more nuanced now that 7.2 mg is approved, the answer is that there are two licensed maintenance levels, and which one is appropriate is a clinical call.

For context on what treatment typically costs through a private service (including what a reputable provider's price should include) the weight-loss treatments page covers the detail.

What happens if maintenance dosing needs to pause or stop?

This is the question our prescribers hear regularly, and it deserves a straight answer: weight tends to return after semaglutide is stopped. The biology behind that is consistent across the clinical data, the appetite-suppressing effect of the medicine is not permanent, and without it, hunger signals reassert themselves. The period after stopping Wegovy requires a plan, ideally one built with your clinical team before you stop, not after.

Reasons to pause include surgery, pregnancy, intolerable side effects or a clinical decision that the benefit has plateaued. A temporary pause is different from stopping permanently, and your prescriber will advise on whether re-starting makes sense and at what dose. If you want a broader picture of what ongoing treatment involves, our overview of the Wegovy maintenance plan covers what to expect and how to approach each stage with your prescriber. Never adjust or stop your maintenance dose based on what you've read online, the SmPC and your prescriber's advice take precedence over everything else. Pregnancy and breastfeeding are clear contraindications; semaglutide is not recommended for those who are pregnant, breastfeeding or actively trying to conceive, and it is not licensed for anyone under 18.

If you have questions about where your treatment is headed, or you're considering starting for the first time, our clinical team is the right starting point. A review with a real prescriber (not an automated questionnaire) shapes the plan.